Clinical outcomes and toxicities of pazopanib administered orally in crushed form: Case reports and review of the literature. (January 2020)

• Record Type: Journal Article
• Authors: Stein, Jill; Milhem, Mohammed; Vaena, Daniel
• Is Part Of: Journal of oncology pharmacy practice. Volume 26:Number 1(2020)
• Page Start: 232
• Page End: 235
• Publication Date: 2020-01
• Subjects: Bioavailability -- chordoma -- pazopanib -- renal cell carcinoma -- swallowing tablet crushing; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155219841108
• Languages: English
• ISSNs: 1078-1552

Abstract

Cancer treatment has changed dramatically with the development of oral targeted therapies. Pazopanib, an oral VEGF tyrosine kinase inhibitor, is currently approved for advanced renal cell carcinoma, advanced soft tissue sarcoma, and is being studied for various tumor types. Due to the potential of increased exposure to pazopanib when crushed, pazopanib should be given as an intact whole tablet. Thus, in patients with difficulty swallowing medications or feeding tubes, pazopanib is usually not considered to be an option. Here, we describe two cases which show the administration of crushed pazopanib was feasible and had apparent clinical activity.